Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Most Cited Paper
in Immunotherapy and Immune Responses
18 Months Post-Publication
Class of 2026
“Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/
Topics
JAK1 inhibition · itacitinib · PD-1 inhibition · Type I interferon (IFN-I) · Chronic inflammation · immunosuppression · Non-small cell lung cancer · Phase II clinical trial · CD8 T cell plasticity · T cell exhaustion · effector memory-like T cells · T cell clonotypes · terminal differentiation · combination immunotherapy · antitumor immune response · mouse tumor model · progressive disease · immune checkpoint blockade resistance · cytokine-driven immune dysfunction · T cell differentiation dynamics
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459